NAME,DISTRIBUTION,DESCRIPTION,SOURCE,NOTES,CATEGORY,"WORKING NOTES, QUERIES, ACTIONS"
d.ptltfu,"B(3.6,68.4)",pre-treatment loss to follow up,assume 5% (95%uCI=10%),,Common,Bolded names col 1 are parms more funamental to corresponding labels
d.idh.pphc,"B(31.5,3.5)",IDH: proportion of patients who initially present at PHC,assume 90 (95% 80-100),"Table 1, p6 - Confirmed",Location,Look at intervention phase data for interest (sense checking)
d.iph.pphc,"B(31.5,3.5)",IPH: proportion of patients who initially present at PHC,assume 90 (95% 80-100),"Table 1, p6 - Confirmed",,Look at intervention phase data for interest (sense checking)
d.ipd.pphc,"B(31.5,3.5)",IPD: proportion of patients who initially present at PHC,assume 90 (95% 80-100),"Table 1, p6 - Confirmed",,Look at intervention phase data for interest (sense checking)
d.soc.pphc,"B(31.5,3.5)",SOC: proportion of patients who initially present at PHC,assume 90 (95% 80-100),"Table 1, p6 - Confirmed",,Look at intervention phase data for interest (sense checking)
d.iph.phc.test7.referDH,1,IPH: people referred to DH from PHC due to ongoing symptoms at 7-day reassessment following bac- clin- initial test,100%. As protocol,"Table 11, p18 Footnote",,
d.ipd.phc.test.referDH,"B(8,2)",IPD: people chosen to be referred to DH from PHC following bac- initial sputum test,Placeholder assumption 80%,"Table 11, p18 Footnote",,Update with intervention phase data
d.ipd.phc.notest.referDH,"B(8,2)",IPD: people chosen to be referred to DH from PHC following initial clinical exam only,Placeholder assumption 80%,"Table 11, p18 Footnote",,Update with intervention phase data
d.soc.phc.test.referDH,"B(8,2)",SOC: people chosen to be referred to DH from PHC following bac- initial sputum test,Placeholder assumption 80%,"Table 11, p18",,Update with observation phase data
d.soc.phc.notest.referDH,"B(8,2)",SOC: people chosen to be referred to DH from PHC following initial clinical exam only,Placeholder assumption 80%,"Table 11, p18",,Update with observation phase data
d.idh.rltfu,"B(4,6)","IDH: referral loss to follow up, all people with presumptive TB referred to DH",Placehold assumption 40%,"Table 12, p19 Footnote",,"Update with intervention phase data. Ideally pathway-specific, but may need to use the same rate for all pathways if little data/wide ranges"
d.iph.rltfu,"B(4,6)","IDH: referral loss to follow up, people referred to DH from PHC due to ongoing symptoms at 7-day reassessment following bac- clin- initial test",Placehold assumption 40%,"Table 12, p19 Footnote",,
d.ipd.rltfu,"B(4,6)","IDH: referral loss to follow up, people chosen to be referred to DH from PHC following either clinical exam only or bac- sputum test",Placehold assumption 40%,"Table 12, p19 Footnote",,
d.soc.rltfu,"B(4,6)","SOC: referral loss to follow up, people chosen to be referred to DH from PHC following either clinical exam only or bac- sputum test",Placehold assumption 40%,"Table 12, p19",,
d.dh.prsmptv,"B(2,8)",at DH: patients who fit the definition of presumptive TB,placeholder PJD - make age dpt?,move to epi??,Symptoms,"Update with intervention phase data (i.e. total rate of presumptive cases identified, given 100% presumed assumption"
d.phc.prsmptv,"B(2,8)",at PHC: patients who fit the definition of presumptive TB,placeholder PJD - make age dpt?,,,
d.idh.dh.presumed,1,"IDH, at DH: people assessed as having presumptive TB at initial assessment (of those who fit the definition of presumptive TB)",assume 100%,"Table 2, p7 Footnote",,100 % by defn
d.idh.phc.presumed,1,"IDH, at PHC: people assessed as having presumptive TB at initial assessment (of those who fit the definition of presumptive TB)",assume 100%,"Table 2, p7 Footnote",,
d.iph.dh.presumed,1,"IPH, at DH: people assessed as having presumptive TB at initial assessment (of those who fit the definition of presumptive TB)",assume 100%,"Table 2, p7 Footnote",,
d.iph.phc.presumed,1,"IPH, at PHC: people assessed as having presumptive TB at initial assessment (of those who fit the definition of presumptive TB)",assume 100%,"Table 2, p7 Footnote",,
d.ipd.dh.presumed,1,"IPD, at DH: people assessed as having presumptive TB at initial assessment (of those who fit the definition of presumptive TB)",assume 100%,"Table 2, p7 Footnote",,
d.ipd.phc.presumed,1,"IPD, at PHC: people assessed as having presumptive TB at initial assessment (of those who fit the definition of presumptive TB)",assume 100%,"Table 2, p7 Footnote",,
d.soc.dh.presumed,"B(3.86157,7.171488)","SOC, at DH: people assessed as having presumptive TB at initial assessment (of those who fit the definition of presumptive TB)",assume 40 (20 - 60),"Table 2, p7 - Changed",,Update with observation phase data (i.e. ratio of rate of presumptive cases identified in OP compared to IP)
d.soc.phc.presumed,"B(3.86157,7.171488)","SOC, at PHC: people assessed as having presumptive TB at initial assessment (of those who fit the definition of presumptive TB)",assume 30 (10 - 50),"Table 2, p7 - Changed",,
d.ipd.phc.test.o5,"B(3.5,31.5)","IPD, at PHC: people receiving Xpert Ultra testing [on sputum], in people identified as having presumptive TB",Placeholder assumption10 (0 - 20) [using same assumption as SOC],"Table 7, p13 (=0 in u5)",Testing,"PD: MH to check. MH: Yes, but to update with real data from IPD"
d.soc.dh.test.o5,"B(7.453846,17.39231)","SOC, at DH: people receiving Xpert Ultra testing [either sputum or GA], in those identified as having presumptive TB","30 (?? - ??) [O1 baseline assessment, expert opinion]","Table 7, p13",,
d.soc.dh.test.u5,"B(7.453846,17.39231)","SOC, at DH: people receiving Xpert Ultra testing [either sputum or GA], in those identified as having presumptive TB","10 (0-20) [O1 baseline assessment, expert opinion]","Table 7, p13",,
d.soc.dh.fracsp.o5,"B(1.3733,2.7467)","SOC, at DH: people receiving Xpert Ultra on a sputum sample, of those receiving any Xpert test [the remainder receiving it on a GA sample]","2/3 (?? - ??) [O1 baseline assessment, expert opinion]","Table 7, p13 (=0 in u5)",,
d.soc.phc.test.o5,"B(3.5,31.5)","SOC, at PHC: people receiving Xpert Ultra testing [on sputum], in those identified as having presumptive TB","assume 10 (0 - 20) [O1 baseline assessment, expert opinion]","Table 7, p13 (=0 in u5)",,
ES.poss.phc.o5,"B(4.4375,13.3125)",% of patients identified as having presumptive TB who give an expectorated sputum sample,"25 (5-45) [O1 baseline assessment, expert opinion]","Table 4, p10",Samples,
ES.poss.dh.o5,"B(9.2,13.8)",% of patients identified as having presumptive TB who give an expectorated sputum sample,40 (20-60) [O1 baseline assessment],"Table 4, p10",,
GA.poss.dh.o5,"B(3.5,31.5)",% of patients identified as having presumptive TB who give a GA sample,"10 (0-20) [O1 baseline assessment, expert opinion]","Table 5, p11",,
GA.poss.dh.u5,"B(3.5,31.5)",% of patients identified as having presumptive TB who give a GA sample: <5s,"10 (0-20) [O1 baseline assessment, expert opinion]","Table 5, p11",,
d.soc.phc.smear.o5,"B(3.25,18.4166666666667)",% of patients identified as having presumptive TB who receive smear microscopy on a sputum sample,"15 (0-30) = 60% * ES.poss.phc.o5 [O1 baseline assessment, expert opinion]","Table 6, p12",,
d.soc.dh.smear.o5,"B(5.48888888888889,21.9555555555556)",% of patients identified as having presumptive TB who receive smear microscopy on a sputum sample,"20 (5-35) = 50% * ES.poss.dh.o5 [O1 baseline assessment, expert opinion]","Table 6, p12",,
NPA.poss,"B(7,3)",% patients anywhere in whom NPA sample is possible,placeholder [=??],,,
ST.poss,"B(8,2)",% patients in whom Stool sample possible,placeholder [=??],,,
sens.xstool,"B(21.716911549042,13.5951397502133)",sensitivity of Xpert Ultra on stool in bac+ children,61.5% (44.1% to 76.4%). Kay 2020,"Table 9, p15",Dx accuracy,Update from study??
spec.xstool,"B(480.118305785123,7.31144628099173)",specificity of Xpert Ultra stool in bac+ children,98.5% (97.0% to 99.2%). Kay 2020,"Table 9, p15",,Update from study??
sens.xnpa,"B(14.876289210384,17.67576595457)",sensitivity of Xpert Ultra on NPA in bac+ children,45.7% (28.9% to 63.3%). Kay 2020,"Table 9, p15",,Update from study??
spec.xnpa,"B(120.278188775511,3.08405612244899)",specificity of Xpert Ultra on NPA in bac+ children,97.5% (93.7% to 99.3%). Kay 2020,"Table 9, p15",,Update from study??
sens.xga,"B(19.4209751059137,7.1831003816393)",sensitivity of Xpert on GA in bac+ children,73.0% (52.9% to 86.7%). Kay 2020,"Table 9, p15",,
spec.xga,"B(212.720785244704,4.11997443389335)",specificity of Xpert on GA in bac+ children,98.1% (95.5% to 99.2%). Kay 2020,"Table 9, p15",,
sens.xsputum,"B(103.163282735012,38.5445232196748)",sensitivity for C+ of Xpert on sputum,72.8% (64.7% to 79.6%). Kay 2020,"Table 9, p15",,
spec.xsputum,"B(520.629938271604,13.3494855967078)",specificity for C+ of Xpert on sputum,97.5% (95.8% to 98.5%). Kay 2020,"Table 9, p15",,
spec.clin,"B(694.552101135748,76.3159356408868)",specificity of clinical dx,0.901 (0.878 - 0.921). Marais 2006,"Table 10, p17",,To be further informed by data from Int arms & other TB-Studies later if possible?!
sens.clin,"B(492.167344045368,292.788547574039)",sensitivity of clinical dx,0.627 (0.592 - 0.661). Marais 2006,"Table 10, p17",,To be further informed by data from Int arms & other TB-Studies later if possible?!
ontx.u5,"LN( -3.963316,0.6457913)",CFR children <5 on TB treatment,Jenkins et al 2017,used in d.cfr.tx,Outcomes,
ontx.o5,"LN(-4.828314,0.4817445)",CFR children 5-14 on TB treatment,Jenkins et al 2017,used in d.cfr.tx,,
hivartOR:mn,"MVN: [2.6375681, -0.5683867]","ORs of death on TB treatment, (OR HIV+ vs -) x (ART -/+): mean","Jenkins et al 2017, Dodd et al 2017",used in d.cfr.tx,,
hivartOR:sg,"MVN: [[0.2325509,-0.2325509],[-0.2325509,0.6367345]]","ORs of death on TB treatment, (OR HIV+ vs -) x (ART -/+): variance","Jenkins et al 2017, Dodd et al 2017",used in d.cfr.tx,,
notx.u5,"LN(-0.830113,0.08035318)",CFR children <5 without TB treatment,Jenkins et al 2017,used in d.cfr.notx,,
notx.o5,"LN(-1.903809,0.1285165)",CFR children 5-14 without TB treatment,Jenkins et al 2017,used in d.cfr.notx,,
notxH.u5,"B(77.13050,11.10817)",CFR children <5 without TB treatment (HIV+/ART-),Dodd et al 2017,used in d.cfr.notx,,
notxH.o5,"B(19.59083,6.89700)",CFR children 5-14 without TB treatment (HIV+/ART-),Dodd et al 2017,used in d.cfr.notx,,
notxHA.u5,"B(15.18683,12.87500)",CFR children <5 without TB treatment (HIV+/ART+),Dodd et al 2017,used in d.cfr.notx,,
notxHA.o5,"B(10.43383,11.08417)",CFR children 5-14 without TB treatment (HIV+/ART+),Dodd et al 2017,used in d.cfr.notx,,
prr,"B(2.1525,69.5975)",prevalence of rifampicin resistance in people with TB,assume 3% (SD=2%),,Epidemiology,Update using country-specific data
d.dh.tbinprsmptv,"B(2,8)","at DH: of presumptive TB, fraction with TB",placeholder PJD - make age dpt?,"CHANGE placeholder?! Table 14, p21 uses 50% (25% - 75%)",,Update using intervention phase data
d.phc.tbinprsmptv,"B(2,8)","at PHC: of presumptive TB, fraction with TB",placeholder PJD - make age dpt?,"CHANGE placeholder?! Table 14, p21 uses 25% (15% - 40%) ",,Update using intervention phase data
d.hivprev.u5,"B(2,8)",HIV prevalence <5,placeholder PJD ,,,Update using country-specific data. Note no difference in cohort by DH vs PHC
d.hivprev.o5,"B(2,8)",HIV prevalence >5,placeholder PJD ,,,Update using country-specific data
d.artcov,"B(8,2)",ART coverage,placeholder PJD ,,,TODO - HIV/ART IRRs. 
d.F.u5,"B(3,3)",fraction of presenting children under 5,placeholder PJD ,,,Update with intervention phase study data
Fbc.u5,"B(17,23)",fraction of children bacteriologically confirmable under 5,Zar,,,
Fbc.o5,"B(3,3)",fraction of children bacteriologically confirmable over 5,placeholder PJD ,,,